327 related articles for article (PubMed ID: 29490654)
21. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
Schuette W; Schirmacher P; Eberhardt WEE; Dietel M; Zirrgiebel U; Muehlenhoff L; Thomas M
BMC Cancer; 2018 Feb; 18(1):135. PubMed ID: 29402243
[TBL] [Abstract][Full Text] [Related]
22. What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.
Lester JF; Agulnik J; Akerborg O; Chouaid C; De Geer A; Finnern HW; Herder GJ; Lungershausen J; Mitchell PL; Vansteenkiste J; Ziske C; Goker E
Lung Cancer; 2013 Oct; 82(1):128-35. PubMed ID: 23910909
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience.
Sauter JL; Butnor KJ
Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394
[TBL] [Abstract][Full Text] [Related]
24. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
[TBL] [Abstract][Full Text] [Related]
25. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
26. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
[TBL] [Abstract][Full Text] [Related]
27. Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe.
Verleger K; Penrod JR; Manley Daumont M; Solem C; Luo L; Macahilig C; Hertel N
Clinicoecon Outcomes Res; 2020; 12():23-33. PubMed ID: 32021337
[TBL] [Abstract][Full Text] [Related]
28. Real-world healthcare resource utilization in a European non-small cell lung cancer population: the EPICLIN-Lung study.
Vergnenègre A; Carrato A; Thomas M; Jernigan C; Medina J; Cruciani G
Curr Med Res Opin; 2014 Mar; 30(3):463-70. PubMed ID: 24188056
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real-world retrospective observational study.
Cai B; Fulcher N; Boyd M; Spira A
Thorac Cancer; 2021 Jul; 12(14):2055-2064. PubMed ID: 34028984
[TBL] [Abstract][Full Text] [Related]
30. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
[TBL] [Abstract][Full Text] [Related]
31. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
Arriola E; García Gómez R; Diz P; Majem M; Martínez Aguillo M; Valdivia J; Paredes A; Sánchez-Torres JM; Peralta Muñoz S; Barneto I; Gutierrez V; Andrade Santiago JM; Aparisi F; Isla D; Ponce S; Vicente Baz D; Artal A; Amador M; Provencio M
BMC Cancer; 2018 Jan; 18(1):106. PubMed ID: 29382302
[TBL] [Abstract][Full Text] [Related]
32. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study.
Carrato A; Vergnenègre A; Thomas M; McBride K; Medina J; Cruciani G
Curr Med Res Opin; 2014 Mar; 30(3):447-61. PubMed ID: 24168104
[TBL] [Abstract][Full Text] [Related]
33. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage.
Wood R; Taylor-Stokes G
BMC Cancer; 2019 Mar; 19(1):214. PubMed ID: 30849964
[TBL] [Abstract][Full Text] [Related]
34. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
[TBL] [Abstract][Full Text] [Related]
35. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
36. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology.
Marchetti A; Ardizzoni A; Papotti M; Crinò L; Rossi G; Gridelli C; Barberis M; Maiorano E; Normanno N; Taddei GL; Scagliotti G; Clemente C; Pinto C
J Thorac Oncol; 2013 Mar; 8(3):352-8. PubMed ID: 23407559
[TBL] [Abstract][Full Text] [Related]
37. A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non-Small Cell Lung Cancer.
Batra A; Yusuf D; Hurry M; Walton RN; Devost N; Farrer C; Cheung WY
Am J Clin Oncol; 2021 Oct; 44(10):512-518. PubMed ID: 34380947
[TBL] [Abstract][Full Text] [Related]
38. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.
Pompen M; Gok M; Novák A; van Wuijtswinkel R; Biesma B; Schramel F; Stigt J; Smit H; Postmus P
Lung Cancer; 2009 Apr; 64(1):110-6. PubMed ID: 18805601
[TBL] [Abstract][Full Text] [Related]
39. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.
Stepanski EJ; Houts AC; Schwartzberg LS; Walker MS; Reyes CM; Blakely J
Clin Lung Cancer; 2009 Nov; 10(6):426-32. PubMed ID: 19900861
[TBL] [Abstract][Full Text] [Related]
40. Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.
Gobbini E; Galetta D; Tiseo M; Graziano P; Rossi A; Bria E; Di Maio M; Rossi G; Gregorc V; Riccardi F; Scotti V; Ceribelli A; Buffoni L; Delmonte A; Franchina T; Migliorino MR; Cortinovis D; Pisconti S; Bordi P; Catino A; Maiello E; Arizio F; Novello S;
Lung Cancer; 2017 Sep; 111():30-37. PubMed ID: 28838394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]